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Abstract In the present communication, we report the
fabrication of a unique core-shell inorganic nanomaterial
with potential therapeutic and diagnostic functions. It
contains an iron–cobalt (FeCo) core that demonstrates
magnetic resonance imaging (MRI) contrast property and
a thin nanoshell of gold that inhibits the function of a pro-
angiogenic growth factor, VEGF165. Au(FeCo) core-shell
nanomaterials are fabricated in the gas phase and charac-
terized using transmission electron microscopy, energy
dispersive spectrum, inductively coupled plasma analysis,
and MRI. Inhibition of VEGF165 function by Au(FeCo) is
demonstrated against VEGF165/VPF-induced signaling
cascades and proliferation of human umbilical vein endo-
thelial cells (HUVECs). The self-contrast property of Au
(FeCo) is determined in vitro by MRI after incubating
HUVECs with Au(FeCo), demonstrating intrinsic contrast
property of this potentially therapeutic nanomaterial. In
brief, we report here the successful fabrication of an
inorganic core-shell nanomaterial with potential therapeutic
and diagnostic functions. It inhibits the function of
VEGF165 and functions as a MRI contrast agent.
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1 Introduction
It is recognized that nanotechnology has the potential to
play an important role in human health care including
angiogenesis (Gannon et al. 2008; Goldstein et al. 1995;
Goodman et al. 2004; Han et al. 2007; Hong et al. 2006;
Liu et al. 2007; Paciotti et al. 2004; Patra et al. 2008a; Patra
et al. 2008b; Shaw et al. 2008; Sokolov et al. 2003;
Sullivan and Ferrari 2004). Vascular endothelial growth
factor 165 (VEGF165) plays a major role in angiogenesis
by engaging VEGFR2 on endothelial cells, turning on a
number of signaling cascades leading to endothelial cell
proliferation, migration, survival, etc. (Ferrara and Kerbel
2005; Folkman 2007; Folkman and Hanahan 1991; Dvorak
et al. 1999). Anti-angiogenic agents presently used in the
clinics exhibit serious toxicities (Bhattacharya et al. 2004;
Bhattacharya et al. 2007; Mukherjee et al. 2007; Mukherjee
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et al. 2005). Furthermore, monitoring the effect of anti-
angiogenic therapy is also a challenge. Thus, there is a
clear need to discover new anti-angiogenic molecules that
will exhibit low toxicity and monitor the effect of the anti-
angiogenic therapy by self-contrast. Here, we report the
fabrication of a unique core-shell inorganic nanomaterial
with such an endogenous therapeutic and diagnostic
function. It contains an iron–cobalt (FeCo) core that
demonstrates magnetic resonance imaging (MRI) contrast
property and a thin nanoshell of gold that inhibits the
function of a pro-angiogenic growth factor, VEGF165. It
is also important to consider the possible toxic effects of
this nanomaterial. Since the nanoparticles are in a core-
shell structure, only gold is exposed to the cells or any
outside environment, and FeCo alloy is prevented from
contacting anything else but gold. It is general agreement
that gold is noncytotoxic based on a range of studies
about modified gold nanoparticles.
Au(FeCo) core-shell nanomaterials are fabricated in the
gas phase and characterized using transmission electron
microscopy (TEM), energy dispersive spectrum (EDS),
inductively coupled plasma-mass spectrometry (ICP-MS)
analysis. Inhibition of VEGF165 function by Au(FeCo)
was demonstrated against VEGF165/VPF-induced signal-
ing cascades and proliferation of human umbilical vein
endothelial cells (HUVECs). Challenging the VEGF165
function in the presence of Au(FeCo) demonstrates the
inhibition of VEGF165/VPF-induced proliferation of
HUVECs and inhibition of phosphorylation of VEGF
receptor 2 (VEGFR2) by this nanomaterial in a dose-
dependent manner. However, FeCo alone, without a gold
nanoshell, does not inhibit the VEGF165/VPF-induced
proliferation of HUVECs nor does it inhibit the
VEGF165/VPF-induced VEGFR2 phosphorylation. In the
absence of VEGF165/VPF, either Au(FeCo) or FeCo did
not affect the HUVEC proliferation, suggesting the non-
toxic behavior of this nanocomposite material. In addition,
the self-contrast property of Au(FeCo) was determined in
vitro by MRI after incubating HUVECs with Au(FeCo),
demonstrating the significant contrast behavior of the cells
upon nanomaterial treatment compared to non-treated
control cells or phospate-buffered saline (PBS). Further-
more, intracellular uptake studies determined by ICP
demonstrate a dose-dependent uptake and contrast behavior
of Au(FeCo). In brief, we report here the successful
fabrication of an inorganic core-shell nanomaterial with
potential therapeutic and diagnostic functions. It inhibits the
function of VEGF165 and functions as a MRI contrast
agent. The potential biomedical applications of this nano-
material are enormous. In addition, the presence of a gold
nanoshell endows flexibility to this material to surface
modification for a wide variety of biological applications
including targeting.
2 Experimental
2.1 Synthesis and characterization of Au(FeCo)
and FeCo nanoparticles
The FeCo–Au core-shell nanoparticles were synthesized
directly in gas phase by a novel “snapshot synthesis” method
(Xu and Wang 2007, 2008). The experimental apparatus
consisted of a sputtering–gas–condensation source and a
deposition chamber. A Fe:Co:Au (35:15:50) composite target
was used to synthesize the FeCo–Au core-shell nanoparticles.
The vapor of a mixture of Fe, Co, and Au atoms was generated
by sputtering process. The atoms were cooled down by the
collisions between the atoms and inert gas molecules, which
then nucleate and grow into nanoparticles. The core-shell
structure was formed by segregating the Au to the surface of
the nanoparticles through heat-assisted diffusion during
synthesis. The formed nanoparticles were carried out of the
source by the gas flow and collected in the deposition
chamber. Polyethylene glycol (PEG)-coated glass substrates
were used to collect the nanoparticles and transfer them into a
solution (H2O). Cu grids covered with amorphous carbon
were used for the preparation of TEM samples.
The core-shell structure of FeCo–Au nanoparticles was
confirmed by EDS line scan on a single nanoparticle. FeCo-
Au nanoparticles were directly deposited on amorphous
carbon covered Cu grids. Analysis was done under STEM
mode on a field emission gun TEM (FEI Tecnai G2 F30)
equipped with an EDS detector. Electron beam scanned
across a single FeCo–Au nanoparticle by 1 nm step in the
designated direction. A distribution spectrum of Fe, Co, and
Au in a nanoparticle was obtained.
2.2 [3H]thymidine incorporation experiments
Proliferation experiments using [3H]thymidine incorpora-
tion were performed as described previously (Mukherjee et
al. 2005). In brief, serum-starved HUVECs were treated
with VEGF165 (10 ng/mL) either free or conjugated to
different doses of Au(FeCo) or FeCo. After 24 h, cells were
treated with 1 μCi of thymidine for 4 h, followed by
washing in PBS, fixing the cells in cold methanol, and
lysing the cells with 0.1 N NaOH. The cell lysates were
read in a scintillation counter for thymidine incorporation.
2.3 Western blot analysis of VEGFR2 phosphorylation
Effect of Au(FeCo) and (FeCo) on VEGFR2 phosphorylation.
Western blot analysis of phospho-VEGFR2 (p-VEGFR2) and
total VEGFR2 from (1) control untreated HUVECs ,(2) A,
serum-starved HUVECswere stimulated for 5 min withVEGF
(10 ng/mL) as a positive control, (3–5) HUVECs treated with
VEGF165 while conjugated to Au(FeCo) or (FeCo) at various
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concentrations [3=100 ng, 4=1 µg, and 5=10 µg of Fe–Co–
Au], and (6–8) HUVECs treated with Fe–Co at various
concentrations [6=100 ng, 7=1 µg, and 8=10 µg of Fe–Co].
Afterwards, the incubation cells were lysed with RIPA buffer
containing PIC and halt. Cell lysates were isolated and
Western blot analysis run according to literature procedure
(Mukherjee et al. 2005).
2.4 Intracellular uptake of Au(FeCo)
HUVECs were grown in 100-mm collagen-coated tissue
culture plates in triplicates in EGM medium and treated
with different doses of (FeCo)Au for 2 h. Afterwards, the
incubation cells were washed extensively in PBS thrice.
Finally, the cells were trypsinized, pooled together, thor-
oughly washed in PBS again, and finally resuspended in
PBS for ICP analysis for gold.
2.5 Magnetic resonance imaging
Samples were evaluated on 1.5 and 3 T clinical systems (GE
Twin Speed EXCITE, GE Healthcare, Waukeshau, WI).
Samples contained in 1-ml microcentrifuge tubes were placed
in a styrofoam tube holder which was then positioned in the
center of a birdcage head coil. Following three-plane single-
shot fast spin echo localizing sequences, T2* and R2*
measurements were performed using a multi-echo gradient
echo sequence. Eight echo times (TEs) were acquired, with
the following sequence parameters: TR (repetition time)
150 ms, TE 2.6–33.8 ms, flip angle 20, bandwidth 50 kHz,
slice thickness of 5 mm, field of view 14 cm, imaging matrix×
256×160, two signals averaged. An axial slice was acquired
through the bottom of the sample tubes.
Calculation of T2* and R2* was performed using Cine
Tool software installed on a GE Advantage Windows 4.3
workstation (GE Healthcare, Waukeshau, WI). A region of
interest (ROI) encompassing the bottom of the sample tube
was placed on the image with the shortest TE and then copied
to the remaining seven images with progressively longer TEs.
The average signal intensity of each ROI was then measured
and plotted versus TE, and the resulting data were fit to the
expected single exponential decay curve describing the loss of
transverse magnetization in the sample to solve for T2* and
R2* (S=S0e -TE/T2*+S1, where S=signal intensity in
arbitrary units, S0 and S1 are constants, and TE is the echo
time. R2*, the relaxivity, is the inverse of T2*).
3 Results and discussion
The Au(FeCo) core-shell nanoparticles were synthesized
directly in the gas phase by a novel “snapshot synthesis”
method (described in the “Section 2” section) (Xu and
Wang 2008). A Fe:Co:Au (35:15:50) composite target was
used to synthesize the FeCo-Au core-shell nanoparticles
and collected in the deposition chamber of PEG-coated
glass. The nanoparticles thus obtained were transferred to
water and characterized by TEM. Figure 1 represents the
TEM micrographs of Au(FeCo) and FeCo nanoparticles.
The average size of the Au(FeCo) core-shell nanoparticles
is 25.36 nm, with a standard deviation of 1.92 nm
(Fig. 1a, b). The composition is (Fe70Co30)50Au50 atomic
percent. For comparison, Fe70Co30 nanoparticles with
natural oxide shell were also used (Fig. 1c, d). Core-shell
structure is further confirmed by composition mapping of a
single core-shell nanomaterial. Figure 2 shows the compo-
sition mapping of a single Au(FeCo) nanoparticle. Uni-
formly distributed Au shell is confirmed. EDS scan was
conducted along the direction indicated by the red line
(Fig. 2a). It could be seen from Fig. 2b that FeCo forms the
core while Au is dominantly in the shell for the investigated
nanoparticle. The highly uniform morphology of these Au
(FeCo) nanoparticles (Fig. 1a, b) suggests that composition
variation should be small and the diffusion of Au element
to a similar extent in each particle. Therefore, the universal
FeCo-Au core-shell structure is obtained.
To determine the effect of these nanoparticles to
inhibit VEGF165 function, VEGF165-induced prolifera-
tion of HUVECs was performed in the presence and the
absence of Au(FeCo) and FeCo (details are in the
“Section 2”). Figure 3 represents the VEGF165-induced
proliferation of HUVECs in the presence or absence of Au
(FeCo) and FeCo. The figure clearly demonstrates a
significant induction of proliferation (∼threefold) when
HUVECs were stimulated with 10 ng/ml VEGF165.
VEGF165-induced proliferation of HUVECs was signifi-
cantly inhibited (nearly 50%) in the presence of Au
(FeCo), confirming the inhibition of VEGF165 function
by Au(FeCo). In the absence of VEGF165, either Au
(FeCo) or (FeCo) did not affect the basal HUVEC
proliferation, suggesting the non-toxic behavior of these
nanomaterials. Moreover, FeCo core alone did not inhibit
the VEGF165-induced proliferation of HUVECs (Fig. 3b).
These results confirm that the inhibition of VEGF165
function is due to the gold nanoshell present in Au(FeCo)
and not due to the (FeCo) core.
To further confirm whether the inhibition of HUVEC
proliferation was due to inhibition of VEGF165 function by
Au(FeCo), we investigated the downstream signaling events
induced by VEGF165. It is established that VEGF165
engages VEGFRs on endothelial cells leading to receptor
dimerization and subsequently receptor phosphorylation at
different tyrosine residues.(Mukherjee et al. 2005) Therefore,
we wanted to test whether treatment of HUVECs with Au
(FeCo) and FeCo had any effect on VEGFR2 phosphoryla-
tion (details are in the “Section 2”). VEGF165-induced
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phosphorylation of VEGFR2 was significantly inhibited
when HUVECs were treated with 100 ng–10 μg of Au
(FeCo) (Fig. 3c). However, under similar conditions, same
doses of FeCo had no significant effect on VEGFR2
phosphorylation, further confirming our observation obtained
from HUVEC proliferation experiments. The inhibition of
VEGFR2 phosphorylation suggests that Au(FeCo) directly
binds to VEGF165 and inhibits its function, leading to
abrogation of receptor phosphorylation. These results are in
agreement with our previous reports on the anti-angiogenic
property of gold nanoparticles (Bhattacharya et al. 2004;
Mukherjee et al. 2005; Bhattacharya and Mukherjee 2008).
However, we do not rule out the possibility of the
involvement of other mechanisms as well that will be
investigated in the future.
After confirming the inhibition of VEGF165 function by
Au(FeCo), we wanted next to determine the imaging
Fig. 2 Elemental mapping of a core-shell nanomaterial. a The
HADDF image of a Au(FeCo) nanoparticle that was analyzed by
EDS line scan. b Distribution of Fe, Co, and Au element in the
nanoparticle
Fig. 1 TEM micrographs of Au
(FeCo) and FeCo nanoparticles.
a, b Low- and high-
magnification images of Au
(FeCo) nanoparticles, respec-
tively. c, d Low- and high-
magnification images of FeCo
with natural oxide cell
Fig. 3 Effect of Au(FeCo) and (FeCo) nanoparticles onVEGF165-induced
proliferation of HUVECs at various concentrations (0.1–10 µg/mL),
observed by [3H]thymidine incorporation (cell proliferation) assay, pre-
sented as fold of stimulation. a VEGF165-induced proliferation of
HUVECs in the presence of Au(FeCo). Au(FeCo) nanoparticles were
pre-incubated with and without VEGF (10 ng/mL) for 30 min at 4°C,
added to HUVEC starved with (0.1% serum) for 24 h in 24-well plates,
and incubated for 24 h. After 24 h of incubation with nanoparticles, 1 μCi
[3H]thymidine was added into each well. Four hours later, cells were
washed with cold PBS, fixed with 100% cold methanol, and the lysate
collected with 0.1(N) NaOH for measurement of radioactivity. Experiments
were repeated in triplicate. b VEGF165-induced proliferation of HUVECs
in the presence of (FeCo). Experiments were performed similarly as
described above. c Western blot analysis of VEGFR2 upon nanoshell
treatment. Effect of Au(FeCo) and (FeCo) on receptor phosphorylation.
Western blot analysis of phopho-KDR (p-VEGFR2) and total KDR
(VEGFR2) from (1) control untreated HUVECs, (2) A, serum-starved
HUVECs were stimulated for 5 min withVEGF (10 ng/mL) as a positive
control, (3–5) HUVECs treated with Fe–Co–Au at various concentrations
[3=100 ng, 4=1 µg, and 5=10 µg of Fe–Co–Au], and (6–8) HUVECs
treated with Fe–Co at various concentrations [6=100 ng, 7=1 µg, and
8=10 µg of Fe–Co]
b
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property of this nanomaterial. We resorted to MRI
technique as FeCo has the highest saturation magnetization.
Cells are treated with different doses of Au(FeCo) and fixed
in formalin before imaging.
The results are shown in Fig. 4a where R2* (relaxivity)
is plotted against different doses of sample at 3 T. When
cells were treated with Au(FeCo), a dose-dependent
increase in R2* and a progressive decrease in T2* (the
time constant describing the rate at which the phase
coherence of spins in the transverse plane decays following
an initial radiofrequency pulse) values were obtained before
reaching a plateau at ∼32 μg/ml, clearly confirming that Au
(FeCo) retains its MRI contrast properties after treatment
with cells (Rad et al. 2007) Furthermore, R2* values were
significantly higher in the cells incubated with nano-
particles compared with the control cell samples, indicating
the potential of these nanoparticles to serve as MR contrast
agents.
Fig. 4 Intracellular uptake and MRI experiments with HUVECs
treated with Au(FeCo). Figure 4a showing the plot of R2* and T2*
against sample doses exhibiting significant relaxivity of Au(FeCo) and
cells treated with the same (a). Cells were treated with different doses
of (FeCo)Au for 2 h followed by extensive washing in PBS, finally
fixed in 4 % formalin before MRI. b Intracellular uptake of (FeCo)Au
in terms of Au content. HUVECs were grown in 100 mm collagen-
coated tissue culture plates in triplicates and treated with different
doses of (FeCo)Au for 2 h, washed extensively in PBS thrice. Finally,
the cells were trypsinized, pooled together, thoroughly washed in PBS
again, and finally resuspended in PBS for ICP analysis for gold
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FeCo cores of Au(FeCo) nanoparticles induce local
magnetic field inhomogeneities which in turn cause a
significant reduction in T2* (Rad et al. 2007; Bai and
Wang 2005). This, in turn, means that samples with smaller
values of T2* (or longer values of R2*) reflecting higher
concentrations of iron will show more rapid signal decay on
images with successively longer TEs. While many factors
affect the intrinsic tissue relaxation times, the presence of
iron typically represents the dominant contribution, and
therefore measurements of T2* or R2* (relaxivity, or the
inverse of T2*) can be related to the tissue concentration of
iron (Alustiza et al. 2004). It may be noted that T2* does
not decrease as much and its nearly reaching a plateau
around 32 μg/ml may be due to the saturation uptake of the
nanomaterial by the HUVECs. This is further confirmed by
quantifying intracellular uptake of the core-shell materials
in HUVECs by ICP analysis in terms of gold content.
Figure 4b describes the dose-dependent uptake of the core-
shell nanomaterials in terms of gold. The figure clearly
demonstrates that the intracellular uptake reaches a plateau
between 16 and 32 μg/ml of the core-shell nanomaterial
(∼6–12 μg/ml in terms of Au). Thus, there is no further
significant decrease in T2* beyond these points.
4 Conclusions
Taken together, the results confirm that the core-shell
nanoparticles presented in this report are intrinsically
multifunctional. Our results demonstrate the fabrication of
Au (FeCo), a core-shell inorganic nanoparticle, containing
potential therapeutic as well as diagnostic functions. Au
(FeCo) inhibits the function of pro-angiogenic VEGF165
and hence inhibits VEGF165-induced proliferation of
HUVECs and inhibits VEGFR2 phosphorylation. In vitro
imaging by MRI confirms the self-contrast behavior of this
nanomaterial and demonstrates the significant relaxation of
the cells when treated with Au(FeCo) compared to control
cells and PBS. To the best of our knowledge, this
nanoparticle represents the first example of an inorganic
nanoparticle with endogenous dual functionality. Thus, this
nanomaterial can be used as a diagnostic as well as a
therapeutic agent. In the future, this theranostic material
may be utilized not only for the therapeutic and diagnostic
application of angiogenesis-dependent disorders but may
also help to monitor the effect of the treatment on the
disease outcome.
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